Novel Perbutyrylated Glucose Derivatives of (-)-Epigallocatechin-3-Gallate Inhibit Cancer Cells Proliferation by Decreasing Phosphorylation of the EGFR: Synthesis, Cytotoxicity, and Molecular Docking

Ya Wang 1,2,*, Xiao-Jing Shen 3,†, Fa-Wu Su 4,†, Yin-Rong Xie 1,2, Li-Xia Wang 1,2, Ning Zhang 1,2, Yi-Long Wu 1,2, Yun Niu 1,2, Dong-Ying Zhang 1, Cheng-Ting Zi 1,*,‡, Xuan-Jun Wang 1,* and Jun Sheng 1,2,*

1 Key Laboratory of Pu-er Tea Science, Ministry of Education, College of Science, Yunnan Agricultural University, Kunming 650201, China; wangya9188@126.com (Y.W.); xyr351527080@163.com (Y.-R.X.); wanglingxia0315@163.com (L.-X.W.); zn11935594574@163.com (N.Z.); ynuawuyl@126.com (Y.-L.W.); niuyun0429@163.com (Y.N.); zhangdongyings65@163.com (D.-Y.Z.)
2 College of Food Science and Technology, Yunnan Agricultural University, Kunming 650201, China
3 Party Committee of Organ, Yunnan Agricultural University, Kunming 650201, China; sxj24@sina.com
4 State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan Agricultural University, Kunming 650201, China; su_faw@126.com
† These authors contributed equally to this work.
* Correspondence: 2015055@ynau.edu.cn (C.-T.Z.); jwang@ynau.edu.cn (X.-J.W.); shengj@ynau.edu.cn (J.S.); Tel.: +86-159-1257-9655 (C.-T.Z. & X.-J.W. & J.S.); Fax: +86-871-6522-3261 (C.-T.Z. & X.-J.W. & J.S.)

Citation: Wang, Y.; Shen, X.-J.; Su, F.-W.; Xie, Y.-R.; Wang, L.-X.; Zhang, N.; Wu, Y.-L.; Niu, Y.; Zhang, D.-Y.; Zi, C.-T.; et al. Novel Perbutyrylated Glucose Derivatives of (-)-Epigallocatechin-3-Gallate Inhibit Cancer Cells Proliferation by Decreasing Phosphorylation of the EGFR: Synthesis, Cytotoxicity, and Molecular Docking. Molecules 2021, 26, 4361. https://doi.org/10.3390/molecules26144361

1. Introduction

Lung cancer is one of the most commonly occurring cancer mortality worldwide, accounting for 20% of all cancer-related deaths [1]. Approximately 75–85% of lung cancers are non-small-cell lung cancer (NSCLC), including lung adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma (LCC) histological subtypes, and are typically diagnosed at advanced stages [2,3]. Recently, the identification of key oncogenic-driver mutations has led to the development of molecular targeted therapies for patients with NSCLC [4]. The epidermal growth factor receptor (EGFR) plays an important role in cellular functions, and approximately 50% of lung cancer patients possess EGFR overactivated [5]. Thus, EGFR tyrosine kinase has become an attractive therapeutic target for NSCLC [6–8].
EGFR tyrosine kinase inhibitors (TKI), such as gefitinib and erlotinib are used in clinical therapy to treat NSCLC [9–12]. However, the T790M mutation of EGFR has led to resistance to these EGFR TKIs [13], and new drugs have been developed, such as afatinib [10,14] and osimertinib [15]. Natural products and their derivatives with various structures, unique biological activities, and specific selectivity have served as lead compounds for EGFR. For example, aeroplysinin selectively inhibits EGFR [16]; shikonin preferentially inhibits cell proliferation by inhibiting EGFR-signaling [17].

Green tea (Gamellia sinensis) leaves is an extremely popular drink in the world, and many studies show the positive effects of green tea on cancer, including lung cancer [18,19]. It is generally agreed that tea catechins were first isolated from green tea, making it a promising chemopreventive agent [20]. The major catechins in green tea leaves are (-)-epicatechin (EC, 1), (-)-epicatechin-3-gallate (ECG, 2), (-)-epigallocatechin (EGC, 3), and (-)-epigallocatechin-3-gallate (EGCG, 4) (Figure 1). Among these catechins, EGCG is the most studied due to its abundance, constituting 50–80% of total catechins content in green tea [21], and has been reported to have stronger physiological activities than others [22–24]. Several studies have indicated that treatment with EGCG inhibits tumor incidence such as skin, lung, liver, breast, prostate, and stomach [25]. There is considerable evidence that EGCG inhibits tumorigenesis, signal transduction pathway, cell invasion, angiogenesis, and metastasis [26–30]. Notably, previous studies reported that EGCG inhibits the activation of EGFR and human epidermal growth factor receptor 2 (HER2) in human lung cancer cells [31,32], and EGCG inhibits the tyrosine kinase activity of EGFR in human A431 epidermoid carcinoma cells [33].

![Figure 1. Structures of (-)-epicatechin (EC, 1), (-)-epicatechin-3-gallate (ECG, 2), (-)-epigallocatechin (EGC, 3), and (-)-epigallocatechin-3-gallate (EGCG, 4).](image)

However, the use of EGCG often has limitations such as easy oxidation [34], low bioavailability [35], and easy hydrolyses by bacterial and possibly host esterases [36]; thus, attempts to use EGCG in the treatment of human neoplasia have been mostly unsuccessful. To obtain more potent analogs and overcome these problems, many EGCG derivatives have been synthesized, including methyl-protected EGCG [37], acetyl-protected EGCG, [38], and EGCG monoester derivatives [39], and most of them exhibited more potent activity than EGCG. Recently, the glycoconjugates of small molecule anticancer drugs have become an attractive strategy in order to improve drug efficacy and pharmacokinetics, in addition to reducing side effects [40–42]. In our previous study, we thus reported that the synthesized glucosylated EGCG derivatives exhibited enhanced cytotoxicity and were more stable [5,43].
Since butyrate is a well-known histone deacetylase (HDAC) inhibitor, and its anticancer effect shows promising therapeutic potential [44], acetyl-protected EGCG analogs exhibited more activity than EGCG [37]. In this study, we synthesized a series of glucoside derivatives of EGCG (7–12) and evaluated for their in vitro anticancer activity against five human cancer cell lines, including HL-60 (leukemia), SMMC-7721 (hepatoma), A-549 (lung cancer), MCF-7 (breast cancer), and SW480 (colon cancer). In addition, Western blotting and molecular docking analyses of these compounds were studied and correlated with their anticancer activity.

2. Results and Discussion

2.1. Chemistry

The synthesis of the (-)-epigallocatechin-3-gallate glucoside derivatives 7–12 was performed according to the reaction pathways illustrated in Schemes 1 and 2. D-glucose and EGCG were used as starting materials. 2,3,4,6-Tetra-O-butyryl-α-D-glucopyranosyl bromide 6 was prepared using the method reported in the literature [45]. EGCG (4) was allowed to react with the above compound 6 in the presence of K$_2$CO$_3$ in acetone at 55 °C for 12 h to obtain peracetyl EGCG glucoside derivatives 7 and 8 in 25–30% yields (Scheme 1). Then, compounds 7 and 8 were treated with KOH solution in CH$_3$OH at 0 °C for 72 h to yield EGCG glucoside derivatives 9 and 10 in 52–55% yields [27]. Finally, the free glucose of compounds 9 and 10 was butyrylated with butyric anhydride in pyridine solution at 0 °C for 12 h to yield perbutyryl EGCG glucoside derivatives 11 and 12 in 80–82% yields (Scheme 2).

All the synthesized compounds were characterized by $^1$H-NMR, $^{13}$C-NMR, electrospray ionization mass spectrometry (ESI-MS), and high-resolution mass spectrometry (HRESI-MS). In the $^1$H-NMR spectra, the formation of the D-glucose residue was confirmed by the resonance of C$_{1'''}$-H/C$_{2'''}$-H signal ($\delta$ 4.54–4.97 ppm) with the coupling constant of the anomeric proton of D-glucose residue ($J_{1'''}/J_{2'''}$ = 7.6 Hz–7.8 Hz) (Table S1). In our early study, the coupling constant of the anomeric proton of the glucose residue ($J_{1-2}$) is typically <4.0 Hz for the α–linkage and >7.6 Hz for the β–linkage [46].
The chemical structures of compounds were further confirmed by 2D-NMR spectra data. Based on the HMBC data (Figure 2), the strong coupling occurred between \(C_{1}^{\prime\prime\prime\prime}-H\) (δ 4.97 ppm) and C-4" (137.3 ppm) of the D ring from the HMBC of compound 7. Similarly, coupling occurred between \(C_{1}^{\prime\prime\prime\prime}-H\) (δ 4.54 ppm) and C-4" (δ 138.5 ppm) of the other glucosyl residue and C-4' (δ 137.9 ppm) of the B ring from the HMBC of compound 8. The chemical shift for the proton at \(C_{4}-H\) exhibited coupling with C-2, C-3; \(C_{2}^{\prime}-H\), \(C_{6}^{\prime\prime}-H\) occurred with C-2 and \(C_{2}^{\prime}\), \(C_{6}^{\prime\prime}-H\) occurred with C-11; and \(C_{2}^{\prime\prime\prime}-H\) occurred with C-11 in both compounds 7 and 8. These results indicated that the \(\beta\)-peracetylated glucoside (H-1''''→C-4") had attached to the EGCG scaffold in compound 7, and two \(\beta\)-peracetylated glucosides (H-1''''→C-4' and H-1''''→C-4") had attached in compound 8.

![Figure 2. HMBC correlations in compounds 7 and 8.](image)

2.2. Evaluation of Anticancer Activity

All EGCG derivatives 7–12 were evaluated for their cytotoxicity against five human cancer cell lines, including HL-60 (leukemia), SMMC-7721 (hepatoma), A-549 (lung cancer), MCF-7 (breast cancer), and SW480 (colon cancer). EGCG (4) and cisplatin were taken as positive control compounds. The screening procedure was based on the standard 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method [47]. Their activities were expressed by the IC\(_{50}\) value (concentration of drug inhibiting 50% cell growth), and the data are presented in Table 1.

| Compounds | IC\(_{50}\) (µM) |
|-----------|-----------------|
| 4         | >40.0           |
| 7         | 29.5 ± 0.10     |
| 8         | 28.2 ± 0.06     |
| 9         | >40.0           |
| 10        | >40.0           |
| 11        | 28.4 ± 1.00     |
| 12        | 22.9 ± 0.23     |
| Cisplatin | 0.8 ± 0.03      |

As shown in Table 1, the majority of glucoside derivatives of EGCG display weak cytotoxicity against all five cancer cell lines, and most of them show higher potency than the control EGCG. Among the glucoside derivatives of EGCG, compounds 11 and 12 showed better growth inhibition than others in four cancer cell lines (HL-60, SMMC-7721, A-549, and MCF), with IC\(_{50}\) values in the range of 22.90–37.87 µM. Interestingly, all glucoside derivatives of EGCG showed good cytotoxicity against A-549 cells except compound 10.
Molecules 2021, 26, 4361

(having IC$_{50}$ > 40 µM). Previously, we reported that the cytotoxic activity of glucosylated EGCG derivatives with a free glucose residue mostly shows weak activity against breast cancer (MCF and MDA-MB-231 cells) [27]. However, our findings indicate that EGCG derivatives with a perbutyrylated glucose residue (11 and 12) lead to increased activity rather than a free glucose residue (11 vs. 9 and 12 vs. 10).

Cancer chemotherapy is often associated with low/non-selectivity of cancer drugs, which attack cancer cells and normal cells, leading to serious side effects. EGCG derivatives 11 and 12 were tested for their growth inhibitory effects on normal human bronchial epithelial cells (BEAS-2B) (Table 1). The IC$_{50}$ values of compounds 11 and 12 (all having IC$_{50}$ > 40 µM), indicated that glucoside derivatives of EGCG showed moderated selectivity toward cancer cells.

2.3. EGCG Derivatives Inhibited Phosphorylation of EGFR and Downstream Signaling Protein in A-549 Cells

To investigate whether the effects of EGCG derivatives 11 and 12 might involve EGFR signaling, we assessed the expression of several key regulators that function within the EGFR signaling pathway. The results showed that treatment with EGCG slightly exhibited P-EGFR, P-AKT, and P-Erk (Figure 3A). Compounds 11 and 12 further exhibited the phosphorylation of EGFR and downstream signaling protein, while the total protein level of EGFR remained unchanged (Figure 3B,C). As shown in Figure 3D,E, it can be observed that EGCG, 11 and 12 can reduce the expression of phosphorylated EGFR, ERK, and AKT proteins. In summary, EGFR signaling may play a significant role in the effects of EGCG derivatives 11 and 12 in A-549 cells.

2.4. Molecular Docking Analysis

To further investigate the potential binding between EGFR and the compounds, molecular docking was performed. The binding modes of compounds 4, 11, and 12 at the ATP-binding pocket of EGFR (PDB code: 2ITY) were shown in Figure 4. As shown in Figure 4, compounds 11 and 12 could be docked into the active site of EGFR, the butyryl group occupies the ATP-binding pocket. The detailed docking results were presented in Table S2. It was observed that the binding energies between EGFR and glucoside derivatives of EGCG 11 and 12 are weak, compared with EGCG. The docking energy for compounds 4, 11, and 12 were −5.18 kcal/mol, 0.47 kcal/mol, and 1.81 kcal/mol, respectively. The complex structures for compounds 11 and 12 were presented in Figure 5. The key residues were labeled and the important molecular interaction including the hydrogen bonds (black dotted lines), hydrophobic interactions (red dotted lines), π-stacking (gray dotted lines), and salt bridges (yellow dotted lines) were summarized in Table 2.

As shown in Figure 5, the molecules in complex with EGFR were analyzed in Figure 5A,B. It was observed that there are three hydrophobic interactions between compound 11 and three residues of EGFR (PHE723, ALA743, LEU844), five hydrogen bonds between 11 and three residues of EGFR (LEU718, MET793, ASN842), and two salt bridges between 11 and two residues of EGFR (LYS745, ARG841). There are seven hydrophobic interactions between compound 12 and seven residues of EGFR (ALA722, PHE723, VAL726, LYS745, MET793, ARG841, and VAL876), three hydrogen bonds between 12 and three residues of EGFR (GLU758, ASP855, and VAL876), one π-stacking and a salt bridge between 12 and the residue of EGFR (LYS745 and ARG841, respectively). Similarly, EGCG was docked into the EGFR are shown in Figure S1, which result in ten hydrogen bonds, one hydrophobic interaction, one π-stacking and one salt bridge, respectively. The presence of more hydrophobic interactions in compounds 11 and 12 seems the key factor for their high activity.
Figure 3. Effects of EGCG and its derivatives 11 and 12 on the EGCG signaling pathway in A-549 cells: (A) A-549 cells treated with various concentrations of EGCG (20, 40, 60 µM); (B) A-549 cells treated with various concentrations of compound 11 (20, 40, 60 µM); (C) A-549 cells treated with various concentrations of compound 12 (20, 40, 60 µM); (D) EGCG, compound 11 and compound 12 P-EGFR quantitative analysis chart; (E) EGCG, compound 11, and compound 12 P-AKT quantitative analysis chart; (F) EGCG, compound 11, and compound 12 P-ERK quantitative analysis chart. The expression levels of the proteins were determined by Western blotting after 24 h with β-tubulin as the loading control. Data represent the average of three independent experiments (mean ± SEM). ** \( p < 0.005 \), *** \( p < 0.001 \) vs. the control.

Figure 4. Proposed binding modes of the small molecules at the site of EGFR: binding modes of EGCG (in red), 11 (in blue), and 12 (in yellow) in the active site of EGFR (PDB code: 2ITY) by overview and zoom-in of ATP-binding pocket.
Figure 5. The details of the binding between EGFR and compounds 11 (A) and 12 (B): the protein is shown as lines; ligand and the key residues are shown as sticks (ligand colors: C cyan, N blue, O red, and H green); hydrogen bonds are shown as black dotted lines; hydrophobic interactions are shown as red dotted lines; π-stacking is shown as gray dotted lines; salt bridges were shown as yellow dotted lines.

Table 2. The residues for molecular interaction between EGFR and compounds 4, 11 and 12.

| Molecules | Hydrophobic Interactions | Hydrogen Bonds | π-Stacking | Salt Bridges |
|-----------|--------------------------|----------------|------------|-------------|
| 11        | PHE723, ALA743, LEU844   | LEU718, MET793 ASN842 | —          | LYS745, ARG841 |
|           | ALA722, PHE723, VAL726, LYS745, MET793, ARG841, VAL876 | GLU758, ASP855, VAL876 | LYS745 | ARG841 |
| 12        |                         |                |            |             |

3. Experimental

3.1. Materials and Methods

D-glucose and n-butyric anhydride were purchased from Aladdin Chemical Co., Ltd. (Guangzhou, China); (-)-epigallocatechin-3-gallate was obtained from Chengdu Proifa Technology Development Co., Ltd. (Chengdu, China); boron trifluoride etherate was obtained from J&K Chemical Technology Co., Ltd. (Beijing China); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma-Aldrich (St. Louis, MO, USA). All reagents were commercially available and used without further purification unless indicated otherwise. The melting points were measured by an X-4 melting point apparatus and were uncorrected. Optical rotations were obtained with a Jasco P-1020 Automatic Digital Polariscope MS data were obtained in the ESI mode on API Qstar Pulsar instrument; HRMS data were obtained in the ESI mode on LCMS-IT-TOF (Shimadzu, Kyoto, Japan); 1H-NMR and 13C-NMR spectra were recorded on Bruker DRX-500 (Bruker BioSpin GmbH, Rheinstetten, Germany) instruments, using tetramethylsilane (TMS) as an internal standard: chemical shifts (δ) are given in ppm, coupling constants (J) in Hz, the solvent signals were used as references (CD3OD: δC = 49.0 ppm; residual CH3OH in CD3OD: δH = 4.78 ppm). Column chromatography (CC): silica gel (200–300 mesh; Qingdao Makall Group CO., LTD; Qingdao; China). All reaction was monitored using thin-layer chromatography (TLC) on silica gel plates, which was visualized by ultraviolet light (254 nm) and/or 10% phosphomolybdic acid/EtOH. The human cancer cell lines (HL-60, SMMC-7721, A-549, MCF-7, and SW480) were obtained from a Shanghai cell bank in China.
3.2. Chemistry

General procedure for the synthesis of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl (-)-epigallocatechin-3-gallates (7 and 8)

A solution of EGCg (1.8 g, 4 mmol) was dissolved in acetone (5 mL), and potassium carbonate (K₂CO₃, 1.1 g, 8 mmol) was added with stirring 30 min, and 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 6 (1.6 g, 4 mmol) was added with heating and stirring at 55 °C for 12 h. The mixture was cooled and filtered, the filtrate was concentrated under vacuum, and the residue was purified by column chromatography in silica gel (CHCl₃/CH₂OH, 15:1 → 9:1) to afford the major product.

[``-O-(``-``-``)',``-O-(``-``-``)',``-O-(``-``-``)',``-O-(``-``-``-``-``)-tetra-O-acetyl-``-D-glucopyranosyl)]-(-)-epigallocatechin-3-gallate (7).

White powder; yield 25%; mp. 100 °C to 101 °C; ¹H-NMR (CDCl₃, 500 MHz) δ 6.91 (s, 2H, C₂"), 6.49 (s, 2H, C₂"), 6.69 (s, 2H, C₆"-H), 5.95 (s, 2H, C₆"-H, C₈-H), 5.54 (bs, 1H, C₂-H), 5.34 (t, 1H, J = 9.0 Hz), 5.24–5.22 (m, 1H, C₃-H), 5.21 (m, 1H), 5.09 (t, 1H, J = 9.0 Hz), 4.97 (d, 1H, J = 9.0 Hz, C¹",H), 4.82 (dd, 1H, J = 5.4 Hz, 12.4 Hz, 4.04 (dd, 1H, J = 2.4 Hz, 12.4 Hz), 3.88–3.84 (m, 1H), 2.98 (dd, 1H, J = 4.6 Hz, 17.6 Hz, C₄-H₄), 2.86–2.83 (m, 1H, C₄-H₄), 2.04–1.99 (m, 12H, 4 × OCH₃); ¹³C-NMR (CDCl₃, 125 MHz) δ 172.5, 171.6, 171.3, 166.8 (C=O), 157.9 (C-5), 157.8 (C-9), 157.2 (C-7), 151.7 (C-3′), 151.6 (C-3′), 137.3 (C-4′), 133.7 (C-4′), 130.7 (C-1′), 128.2 (C-1′′), 110.1 (C-2′′-C-6′′), 106.7 (C-2′′-C-6′′), 102.7 (C-1′′′′), 99.2 (C-10), 96.5 (C-6), 95.8 (C-8), 78.4 (C-2), 74.1, 73.2, 72.9, 70.4 (C-3), 69.7, 62.9 (C-6′′′′), 26.8 (C-4), 20.8 (OCH₃), 20.6 (OCH₃), 20.5 (OCH₃), 20.5 (OCH₃); ESIMS: m/z 811 [M + Na]⁺.

[``-O-(``-``-``)',``-O-(``-``-``)',``-O-(``-``-``)-tetra-O-acetyl-``-D-glucopyranosyl)-``-O-(``-``-``)-tetra-O-acetyl-``-D-glucopyranosyl)]-(-)-epigallocatechin-3-gallate (8).

White powder; yield 30%; mp. 108 °C to 110 °C; ¹H-NMR (CDCl₃, 600 MHz) δ 6.92 (s, 2H, C₂"), 6.58 (s, 2H, C₂"), 6.58 (s, 2H, C₆"-H), 5.98 (s, 1H, C₃-H), 5.96 (s, 2H, C₆"-H, C₈-H), 5.55 (bs, 1H, C₂-H), 5.04 (s, 1H), 4.67 (d, 1H, J = 9.5 Hz, C¹"-H), 4.54 (d, 1H, J = 9.0 Hz, C¹"-H), 4.41–4.36 (m, 2H), 4.28–4.24 (m, 2H), 3.59–3.55 (m, 2H), 3.51–3.40 (m, 2H), 3.36–3.31 (m, 2H), 3.00 (dd, 1H, J = 12.6 Hz, C₄-H₄), 2.89–2.86 (m, 1H, C₄-H₄), 2.08–2.00 (m, 24H, 8 × OCH₃); ¹³C-NMR (CDCl₃, 150 MHz) δ 173.1, 173.1, 173.1, 173.1, 173.0, 173.0, 173.0, 166.9 (C=O), 158.0 (C-5), 157.9 (C-9), 157.0 (C-7), 151.6 (C-3′-C-5′), 151.3 (C-3′-C-5′), 138.5 (C-4′), 137.9 (C-4′), 134.2 (C-1′), 128.5 (C-1′′), 110.4 (C-2′-C-6′), 107.3 (C-1′′′), 107.1 (C-2′-C-6′), 107.0 (C-1′′′), 99.3 (C-6), 96.8 (C-10), 78.2 (C-2), 77.6, 77.5, 76.2, 76.1, 75.1, 75.0, 71.6, 71.5, 70.7 (C-3), 64.6 (C-6′′′′), 64.5 (C-6′′′′), 62.8 (C-4), 20.9 (OCH₃), 20.9 (OCH₃), 20.8 (OCH₃), 20.8 (OCH₃), 20.8 (OCH₃); ESIMS: m/z 1141 [M + Na]⁺.

General procedure for the synthesis of β-D-glucopyranosyl (-)-epigallocatechin-3-gallates (9 and 10)

To a solution of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl (-)-epigallocatechin-3-gallates 7/8 (0.1 mmol) in CH₂OH (2 mL), a potassium hydroxide solution (0.1 mmol, dissolved in CH₂OH) was added. The mixture was stirred at 0 °C for 72 h and then neutralized with Dowex 50WX4-400 ion-exchange resin to pH = 7. The solvent was evaporated under vacuum, and the residue was purified by column chromatography in silica gel (CHCl₃/CH₂OH, 4:1) to afford the product.

[``-O-(``-``-``)-tetra-O-acetyl-``-D-glucopyranosyl)]-(-)-epigallocatechin-3-gallate (9).

White powder; yield 55%; mp. 118 °C to 120 °C; ¹H-NMR (CDCl₃, 400 MHz) δ 6.90 (s, 2H, C₂"), 6.59 (s, 2H, C₂"), 6.59 (s, 2H, C₆"-H), 6.02 (d, 1H, J = 2.2 Hz, C₆-H), 6.00 (d, 1H, J = 2.2 Hz, C₆-H), 5.73 (bs, 1H, C₃-H), 5.12 (s, 1H, C₂-H), 4.69 (d, 1H, J = 9.0 Hz, C¹"-H), 3.81–3.78 (m, 1H), 3.74–3.72 (m, 1H), 3.49–3.41 (m, 4H), 3.03–3.01 (m, 1H, C₄-H₄), 2.95–2.92 (m, 1H, C₄-H₄); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.4 (C=O), 158.2 (C-7), 157.9 (C-5), 157.8 (C-9), 151.6 (C-3′-C-5′), 146.7 (C-3′-C-5′), 138.6 (C-4′), 133.7 (C-4′), 130.7 (C-1′), 127.6 (C-1′), 110.2 (C-2′-C-6′), 108.2 (C-1′′′), 106.9 (C-2′-C-6′), 98.3 (C-10), 97.1 (C-6), 95.7 (C-8), 78.4, 77.6, 76.3, 75.1, 70.6, 68.6 (C-2), 61.8 (C-6′′′′), 26.5 (C-4); ESIMS: m/z 619 [M−H]⁻.
[4'-O-(β-D-glucopyranosyl)-4''-O-(β-D-glucopyranosyl)]-(+)-epigallocatechin-3-gallate (10)

White powder; yield 52%; mp. 125 °C to 126 °C; 1H-NMR (CD3OD, 400 MHz) δ 6.92 (s, 2H, C2', C6'-H), 6.57 (s, 2H, C2', C6'-H), 5.98 (d, 1H, J = 2.3 Hz, C6-H), 5.96 (d, 1H, J = 2.3 Hz, C5-H), 5.55 (brs, 1H, C3-H), 5.11 (s, 1H, C2-H), 4.67 (d, 1H, J = 9.5 Hz, C1''-H), 4.54 (d, 1H, J = 9.5 Hz, C1'''-H), 3.83 (m, 6H), 3.48–3.41 (m, 6H), 2.99–2.89 (dd, 1H, J = 2.4 Hz, 12.6 Hz, C4-H), 2.89–2.86 (m, 1H, C2-H); 13C-NMR (CD3OD, 100 MHz) δ 166.8 (C=O), 157.9 (C-5), 157.8 (C-9), 156.9 (C-7), 151.5 (C-3', C-5'), 151.2 (C-3, C-5), 134.8 (C-4'), 137.6 (C-1'), 134.1 (C-4'), 128.3 (C-1''), 110.3 (C-2'', C-6''), 107.8 (C-1''''), 107.0 (C-1''''), 106.9 (C-2', C-6'), 99.1 (C-10), 96.6 (C-695.8 (C-8), 78.5, 78.4, 78.4, 78.3 (C-3), 77.5, 77.5, 75.1, 75.1, 70.6, 70.5, 70.4 (C-2), 61.8 (C-6'''''), 61.8 (C-6'''''), 26.7 (C-4); ESI-MS: m/z 781 [M + H]⁺.

General procedure for the synthesis of 2,3,4,6-tetra-O-butyryl-β-D-glucopyranosyl (+)-epigallocatechin-3-gallates (11 and 12)

To a solution of β-D-glucopyranosyl (+)-epigallocatechin-3-gallates 9/10 (0.05 mmol) in pyridine (1 mL), butyric anhydride (0.1 mL, 0.5 mmol) was added, and the stirring was continued at 0 °C for 12 h. The reaction mixture was diluted with CH2Cl2 (5 mL) and washed with aqueous saturated NaHCO3 solution, the organic layer was then dried with Na2SO4, and the solvent was evaporated under vacuum; the residue was purified by column chromatography in silica gel (CHCl3/CH3OH, 15:1) to afford the product.

[4'-O-(2''',3''',4''',5'''-tetra-O-butyryl-β-D-glucopyranosyl)]-(+)-epigallocatechin-3-gallate (II)

White powder; yield 82%; mp. 92 °C to 94 °C; 1H-NMR (CD3OD, 400 MHz) δ 6.91 (s, 2H, C2', C6'-H), 6.48 (s, 2H, C2', C6'-H), 5.94 (s, 2H, C6-H, C8-H), 5.54 (brs, 1H, C7-H), 5.31 (m, 1H), 5.24–5.22 (m, 1H, C3-H), 5.21 (m, 1H), 5.10 (t, 1H, J = 9.0 Hz), 4.97 (d, 1H, J = 9.0 Hz, C1''''-H), 4.29 (dd, 1H, J = 5.4 Hz, 12.4 Hz), 4.06–4.03 (m, 1H), 3.88–3.84 (m, 1H), 2.98 (dd, 1H, J = 4.6 Hz, 17.6 Hz, C6-H), 2.86–2.83 (m, 1H, C4-H), 2.21–2.18 (m, 8H, 4×COCH2), 1.63–1.55 (m, 8H, 4×CH2CH3), 0.94–0.88 (m, 12H, 4×CH2CH3); 13C-NMR (CD3OD, 100 MHz) δ 172.4, 171.6, 171.6, 171.2, 166.8 (C=O), 157.9 (C-5), 157.8 (C-9), 157.1 (C-7), 151.6 (C-3', C-5'), 146.7 (C-3'', C-5''), 137.2 (C-4'), 133.7 (C-4''), 130.7 (C-1''), 128.1 (C-1''), 110.0 (C-2'', C-6''), 106.6 (C-2', C-6'), 102.7 (C-1'''''), 99.2 (C-10), 96.5 (C-6'), 95.8 (C-8), 78.2 (C-2), 74.0, 73.1, 72.9, 70.4 (C-4), 69.7, 62.8 (C-6'''''), 35.9 (COCH2), 35.8 (COCH2), 35.7 (COCH2), 35.6 (COCH2), 26.7 (C-4), 18.2 (CH2CH3), 18.2 (CH2CH3), 18.1 (CH2CH3), 13.6 (CH2CH3), 13.6 (CH2CH3), 13.5 (CH3CH2), 13.5 (CH3CH2); ESI-MS: m/z 923 [M + Na]+.

[4'-O-(2''',3''',4''',6'''-tetra-O-butyryl-β-D-glucopyranosyl)-4''-O-(2''',3''',4''',6'''-tetra-O-butyryl-β-D-glucopyranosyl)]-(+)-epigallocatechin-3-gallate (12)

White powder; yield: 80%; mp. 95 °C to 97 °C; 1H-NMR (CD3OD, 600 MHz) δ 6.92 (s, 2H, C2', C6'-H), 6.58 (s, 2H, C2', C6'-H), 5.98 (s, 1H, C3-H), 5.96 (s, 2H, C6-H, C8-H), 5.03 (brs, 1H, C7-H), 4.68 (d, 1H, J = 9.5 Hz, C1''''-H), 4.56 (d, 1H, J = 9.5 Hz, C1'''-H), 4.42–4.38 (m, 2H), 4.28–4.26 (m, 2H), 3.60–3.56 (m, 2H), 3.50–3.40 (m, 2H), 3.36–3.32 (m, 2H), 3.01 (dd, 1H, J = 2.4 Hz, 12.6 Hz, C4-H), 2.88–2.86 (m, 1H, C4-H), 2.60–2.58 (m, 4H, 2×COCH2), 2.35–2.20 (m, 12H, 6×CH2CH3), 1.62–1.60 (m, 4H, 2×CH2CH3), 1.58–1.56 (m, 12H, 6×CH2CH3), 1.04–0.93 (m, 12H, 6×CH2CH3), 0.91–0.93 (m, 18H, 6×CH2CH3); 13C-NMR (CD3OD, 150 MHz) δ 173.1, 173.1, 173.1, 173.1, 173.0, 173.0, 173.0, 166.9 (C=O), 158.0 (C-5), 157.9 (C-9), 157.0 (C-7), 151.6 (C-3', C-5'), 151.3 (C-3'', C-5''), 138.4 (C-4'), 137.9 (C-4''), 134.1 (C-4'''), 128.5 (C-1'''''), 110.3 (C-2'', C-6''), 107.8 (C-1'''''), 107.1 (C-1'''''), 107.0 (C-2', C-6'), 99.2 (C-6), 99.2 (C-8), 95.9 (C-10), 78.2 (C-2), 77.5, 77.5, 76.1, 76.1, 75.0, 74.9, 71.5, 71.5, 70.6 (C-3), 64.5 (C-6'''''), 64.5 (C-6'''''), 35.9 (COCH2), 35.8 (COCH2), 35.7 (COCH2), 35.7 (COCH2), 35.7 (COCH2), 26.8 (C-4), 18.2 (CH2CH3), 18.2 (CH2CH3), 18.2 (CH2CH3), 18.2 (CH2CH3), 18.1 (CH2CH3), 18.1 (CH2CH3), 18.1 (CH2CH3), 13.6 (CH2CH3), 13.6 (CH2CH3), 13.5 (CH2CH3), 13.5 (CH2CH3), 13.5 (CH2CH3), 13.4 (CH2CH3), 13.4 (CH2CH3); ESI-MS: m/z 1365 [M + Na]+.
3.3. Cytotoxicity Assay

The effects of the (-)-epigallocatechin-3-gallate glucoside derivatives on the survival of cancer cells were determined using the MTT assay. Five human cancer cell lines (HL-60, SMMC-7721, A-549, MCF-7, and SW480) were used in the cytotoxicity assay. All the cancer cells were seeded in 96-well plates and then each tumor cell line was exposed to the test compound at various concentrations in triplicate for 48 h. After the incubation, MTT (100 µg) was added to each well, and the incubation continued for 4 h at 37 °C. After removal of the culture medium, the produced MTT formazan crystals were dissolved with 150 µL DMSO and measured at 492 nm using a microplate reader. The percentage of inhibition was calculated as follows: inhibition ratio (IR, %) = (1 - OD(sample)/OD(control)) × 100%. The experiments were carried out in triplicate, and the IC_{50} (the concentration of drug that inhibits cell growth by 50%) values were determined.

3.4. Western Blotting

A-549 cells were lysed in RIPA buffer containing PMSF (protease and phosphatase inhibitors) and quantified via BCA protein assay. Proteins separated on 8% SDS–PAGE electrophoresis and then blotted onto polyvinyl difluoride membranes. After the membranes were blocked with BSA for 1 h, the expression of various proteins was detected using primary and secondary antibodies conjugated with horseradish peroxidase. HRP was detected using the Prolight HRP Chemiluminescent Kit (Tiangen Biotech, Beijing, China) and FluorChem E Synthem (ProteinSimple, Santa Clara, CA, USA).

3.5. Docking Studies

The X-ray crystal structure of EGCG (PDB code: 2ITY) was retrieved from Protein Data Bank (www.rcsb.org (accessed on 17 February 2020)). Ligand docking was carried out by applying the Lamarckian Genetic Algorithm implemented in AutoDock 4.2. The modeled EGCG structure was employed as the receptor to docking with these small molecules. DiscoveryStudio 4.0 software was used for the preparation of ligand and receptor. Autodock Tools 1.5.6 was used for grid and docking according to the literature [48]. The grid size was set to 60 Å, 60 Å, and 60 Å along the X-, Y- and Z-axis to recognize the binding site. The default 0.375 Å spacing was adopted for the grid box. The number of GA runs was set to 50, and the maximum number of evals (medium) was set to 5,000,000 on AutoGrid 4.2.6 and AutoDock 4.2.6. In the selected cluster, conformations with the lowest binding energy and RMSD (<2.0 Å) were finally chosen to analyze the receptor–ligand interaction. Other miscellaneous parameters were assigned to the default values obtained from the AutoDock 4.2.6.

4. Conclusions

In conclusion, we synthesized a series of glucoside derivatives of EGCG (7–12) and evaluated for their in vitro anticancer activity against five human cancer cell lines, including HL-60, SMMC-7721, A-549, MCF-7, and SW480. All these derivatives display different levels of anticancer activity, which can be affected by the nature of substituents on the glucose residue. Among them, compounds 11 and 12 showed better growth inhibition than others in four cancer cell lines (HL-60, SMMC-7721, A-549, and MCF), with IC_{50} values in the range of 22.90–37.87 µM. EGCG derivatives 11 and 12 also display moderate selectivity toward cancer cells over normal human bronchial epithelial cells (BEAS-2B). The docking study indicated that the presence of more hydrophobic interactions in compounds 11 and 12. In addition, compounds 11 and 12 decreased phosphorylation of EGFR and downstream signaling protein. The most active compounds 11 and 12, both having perbutyrylated glucose residue, led us to conclude that perbutyrylation of the glucose residue causes increased cytotoxic activity, which is indicative of their potential as anticancer agents for further development.
**Supplementary Materials:** The following are available online, Table S1: The characteristic $^1$H-NMR and $^{13}$C-NMR of compounds 7–12, Table S2: The energies of the binding between EGFR and compounds 4, 11, and 12, Figure S1: The details of the binding between EGFR and EGCG (4), Figures S2–S17: Spectra of compound 6–12.

**Author Contributions:** C.-T.Z., X.-J.W., and J.S. conceived and designed the experiments; Y.W., X.-J.S., F.-W.S., Y.-R.X., L.-X.W., N.Z., Y.-L.W., Y.N., D.-Y.Z. and C.-T.Z. performed the experiments; C.-T.Z., Y.W., X.-J.S. and F.-W.S. analyzed the data. D.-Y.Z., C.-T.Z., X.-J.W. and J.S. contributed reagents/materials/analysis tools; C.-T.Z., Y.W., X.-J.S. and F.-W.S. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the National Nature Science Foundation of China (Nos. 31960075, 21602196, and 31760226); the Yunnan Provincial Science and Technology Department (Nos. 2017ZF003, 2017FD084, and 2017FG001-046); the Yunnan Provincial Key Programs of Yunnan Eco-friendly Food International Cooperation Research Center Project (Nos. 2019ZG00904 and 2019ZG00909).

**Institutional Review Board Statement:** Not Applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** The authors thank the staff of the analytical group of the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, for measurements of all spectra.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Compounds 7 and 8 (Scheme 1) are available from the authors. Compounds 9–12 (Scheme 2) are only synthesized on demand.

**References**

1. Torr, L.A.; Siegel, R.L.; Jemal, A. Lung cancer statistics. *Adv. Exp. Med. Biol.* 2016, 893, 1–19.
2. Chen, Z.; Fillmore, C.M.; Hammerman, P.S.; Kim, C.F.; Wong, K.K. Non-small-cell lung cancers: A heterogeneous set of diseases. *Nat. Rev. Cancer* 2014, 14, 535–536. [CrossRef] [PubMed]
3. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. 2012 Global cancer statistics. *CA Cancer J. Clin.* 2012, 65, 87–108. [CrossRef] [PubMed]
4. Tanaka, I.; Morise, M.; Miyazawa, A.; Kodama, Y.; Tamiya, Y.; Gen, S.; Matsui, A.; Hase, T.; Hashimoto, N.; Sato, M.; et al. Potential benefits of bevacizumab combined with platinum-based chemotherapy in advanced non-small-cell lung cancer patients with EGFR mutation. *Clin. Lung Cancer* 2020, 21, 273–280. [CrossRef]
5. Wang, J.; Sun, P.Y.; Wang, Q.; Zhang, P.; Wang, Y.N.; Zi, C.T.; Wang, X.J.; Sheng, J. (-)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells. *Cancer Cell Int.* 2019, 19, 1–16. [CrossRef]
6. Sharma, S.V.; Bell, D.W.; Settlement, J. Epidermal growth factor receptor mutations in lung cancer. *Nat. Rev. Cancer* 2007, 7, 169–181. [CrossRef]
7. Wu, C.H.; Coumar, M.S.; Chu, C.Y.; Lin, W.H.; Chen, Y.R.; Chen, C.T.; Shiao, H.Y.; Rafi, S.; Wang, S.Y.; Hsu, H.; et al. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based pidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and Michael acceptor group for maximal potency. *J. Med. Chem.* 2010, 53, 7316–7326. [CrossRef]
8. Janku, F.; Stewart, D.J.; Kurzrock, R. Targeted therapy in nonsmall-cell lung cancer-is it becoming a reality. *Nat. Rev. Clin. Oncol.* 2011, 8, 384. [CrossRef]
9. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; Pazdur, R. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. *Oncologist* 2003, 8, 303–306. [CrossRef]
10. Gridelli, C.; Rossi, A.; Carbone, D.P.; Guarize, J.; Karachaliou, N.; Mok, T.; Petrella, F.; Spaggiari, L.; Rosell, R. Non-small-cell lung cancer. *Nat. Rev.* 2015, 1, 1–16. [CrossRef]
11. Cohen, M.H.; Johnson, J.R.; Chen, Y.F.; Sridhara, R.; Pazdur, R. FDA drug approval summary: Erlotinib (Tarceva) tablets. *Oncologist* 2005, 10, 461–466. [CrossRef]
12. Shi, B.Y.; Wang, Z.H.; Wang, X.J.; Sheng, J.; Zi, C.T. Recent Advances on Small-Molecule Epidermal Growth Factor Receptor Inhibitors. *Med. Res. 2020*, 4, 20011. [CrossRef]
13. Wang, S.H.; Cang, S.D.; Liu, D.I. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. *J. Hematol. Oncol.* 2016, 9, 1–7. [CrossRef]

14. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L.R.; Padera, R.F.; Shapiro, G.I.; Baum, A.; Himmelsbach, F.; et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene* **2008**, *27*, 4702–4711. [CrossRef]

15. Odogwu, L.; Mathieu, L.; Goldberg, K.B.; Blumenthal, M.B.; Larkins, E.; Fiero, M.H.; Rodriguez, L.; Bijwaard, K.; Lee, E.Y.; Philip, R.; et al. FDA benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor 1790M mutation. *Oncofisch* **2018**, *23*, 353–359. [CrossRef]

16. Hintz, D.; Knebel, A.; Herrlich, P.; Waldmann, H. Synthesis and biological evaluation of aeroplysinin analogues: A new class of receptor tyrosine kinase inhibitors. *Bioorg. Med. Chem.* **1998**, *6*, 1153–1162. [CrossRef]

17. Singh, F.; Gao, D.; Lebwohl, M.G.; Wei, H. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. *Cancer Lett.* **2003**, *200*, 115–121. [CrossRef]

18. Siddiqui, I.A.; Asim, M.; Hafeez, B.B.; Adhami, V.M.; Tarapore, R.S.; Mukhtar, H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. *FASEB J.* **2010**, *25*, 1198–1207. [CrossRef]

19. Bettuzzi, S.; Brausi, M.; Rizzi, F.; Castagnetti, G.; Peracchia, G.; Corti, A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. *Cancer Res.* **2006**, *66*, 1234–1240. [CrossRef]

20. Yang, C.S.; Wang, X.; Lu, G.; Picinich, S.C. Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. *Nat. Rev. Cancer* **2009**, *9*, 429–439. [CrossRef]

21. Khan, N.; Afqa, F.; Saleem, M.; Ahmad, N.; Mukhtar, H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. *Cancer Res.* **2006**, *66*, 2500–2505. [CrossRef]

22. Cabrera, C.; Gimenez, R.; Lopez, M.C. Determination of tea components with antioxidant activity. *J. Agric. Food Chem.* **2003**, *51*, 4427–4435. [CrossRef]

23. Jung, Y.D.; Kim, M.S.; Shin, B.A.; Chay, K.O.; Ahn, B.W.; Liu, W.; Ducans, C.D.; Gallick, G.E.; Ellis, L.M. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. *Br. J. Cancer* **2001**, *84*, 844–850. [CrossRef]

24. Wang, J.; Tang, H.; Hou, B.; Zhang, P.; Wang, Q.; Zhang, B.L.; Huang, Y.W.; Wang, Y.; Xiang, Z.M.; Zi, C.T.; et al. Synthesis, antioxidant activity, and density functional theory study of catechin derivatives. *RSC Adv.* **2017**, *7*, 54136–54141. [CrossRef]

25. Mukhtar, H.; Ahmad, N. Tea polyphenols: Prevention of cancer and optimizing health. *Am. J. Clin. Nutr.* **2000**, *71*, 1698–1702. [CrossRef]

26. Rady, I.; Mohamed, H.; Rady, M.; Siddiqui, I.A.; Mukhtar, H. Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea. *Egypt. J. Basic Appl. Sci.* **2018**, *5*, 1–23. [CrossRef]

27. Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, epigallocatechin-3-gallate (EGCC): Mechanisms, perspectives and clinical applications. *Biochem. Pharmacol.* **2011**, *82*, 1807–1821. [CrossRef]

28. Tyagia, N.; Dec, R.; Begun, J.; Popat, A. Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles. *Int. J. Pharm.* **2017**, *518*, 220–227. [CrossRef]

29. Sajadimajd, S.; Bahramssoltani, R.; Iranpanah, A.; Patra, J.K.; Das, G.; Gaudou, S.; Rahimi, R.; Rezaeamiri, E.; Cao, H.; Giampieri, F.; et al. Advances on Natural Polyphenols as Anticancer Agents for Skin Cancer. *Pharmacol. Res.* **2020**, *151*, 104854. [CrossRef]

30. Zhang, W.J.; Zhang, W.J.; Sun, L.L.; Xiang, L.M.; Lai, X.F.; Li, Q.H.; Sun, S.L. The effects and mechanisms of epigallocatechin-3-gallate on reversing multidrug resistance in cancer. *Trends Food Sci. Technol.* **2019**, *93*, 221–233. [CrossRef]

31. Ma, Y.C.; Li, C.; Gao, F.; Xu, Y.; Jiang, Z.B.; Liu, J.X.; Jin, L.Y. Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. *Oncol. Rep.* **2014**, *31*, 1343–1349. [CrossRef] [PubMed]

32. Deng, P.B.; Hu, C.P.; Xiong, Z.; Yang, H.P.; Li, Y.Y. Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2. *Chin. J. Nat. Med.* **2013**, *11*, 245–253. [CrossRef]

33. Liang, Y.C.; Lin-Shiau, S.Y.; Chen, C.F.; Lin, J.K. Suppression of extracellular signals and cell proliferation through EGFR receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. *J. Cell Biochem.* **1997**, *67*, 55–65. [CrossRef]

34. Hong, J.; Lu, H.; Meng, X.; Ryu, J.H.; Hara, Y.; Yang, C.S. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. *Cancer Res.* **2002**, *62*, 7241–7246.

35. Baba, S.; Osakabe, N.; Natsume, M.; Muto, Y.; Takizawa, T.; Terao, J. In vivo comparison of the bioavailability of (+)-catechin, (+)-epicatechin and their mixture in orally administered rats. *J. Nutr.* **2001**, *131*, 2885–2891. [CrossRef]

36. Park, K.D.; Cho, S.J. Synthesis and antimicrobial activities of 3-O-alkyl analogues of (β)-catechin: Improvement of stability and proposed action mechanism. *Eur. J. Med. Chem.* **2009**, *44*, 1028–1033. [CrossRef]

37. Landis-Piwowar, K.R.; Kuhn, D.J.; Wan, S.B.; Chen, D.; Chan, T.H.; Dou, Q.P. Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs. *Int. J. Mol. Med.* **2005**, *15*, 735–742. [CrossRef]

38. Qsanai, K.; Landis-Piwowar, K.R.; Dou, Q.P.; Chan, T.H. A para-aminostain substrate on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer. *Bioorg. Med. Chem.* **2007**, *5*, 5076–5082. [CrossRef]

39. Mori, S.; Miyake, S.; Kose, T.; Nakaya, T.; Fuller, S.D.; Kato, N.; Kaihatsu, K. Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: Effect of alkyl chain length. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4249–4252. [CrossRef]
40. Calvaresi, E.C.; Hergenrother, P.J. Glucose conjugation for the specific targeting and treatment of cancer. *Chem. Sci.* 2013, 4, 2319–2333. [CrossRef]

41. Lin, Y.S.; Tungpradit, R.; Sinchaikul, S.; An, F.M.; Liu, D.Z.; Phutrakul, S.; Chen, S.T. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters. *J. Med. Chem.* 2008, 51, 7428–7441. [CrossRef]

42. Arafa, H.M.M. Possible contribution of beta-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells. *Investig. New Drugs* 2010, 28, 306–317. [CrossRef]

43. Zhang, X.; Wang, J.; Hu, J.M.; Huang, Y.W.; Wu, X.Y.; Zi, C.T.; Wang, X.J.; Sheng, J. Synthesis and biological testing of novel glucosylated epigallocatechin gallate (EGCG) derivatives. *Molecules* 2016, 21, 620. [CrossRef]

44. Miller, S.J. Cellular and physiological effects of short-chain fatty acids. *Mini Rev. Med. Chem.* 2004, 4, 839–845. [CrossRef]

45. Tamura, M.; Okai, H. Synthesis of 2-acetamido-1-N-(tert-butoxycarbonyl)-l-aspart-1-oyl-(l-phenylalanyl-l-serine methyl ester)-4-oyl]-2-deoxy-β-d-glucopyranosylamine and analogs. *Carbohydr. Res.* 1984, 133, 207–218. [CrossRef]

46. Zi, C.T.; Yang, D.; Dong, F.W.; Li, G.T.; Li, Y.; Ding, Z.T.; Zhou, J.; Jiang, Z.H.; Hu, J.M. Synthesis and antitumor activity of novel per-butyrylated glycosides of podophyllotoxin and its derivatives. *Bioorg. Med. Chem.* 2015, 23, 1437–1446. [CrossRef]

47. Malich, G.; Markovic, B.; Winder, C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cells. *Toxicology* 1997, 124, 179–192. [CrossRef]

48. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.; Goodsell, D.; Olson, A. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 2009, 30, 2785–2791. [CrossRef]